58682-80-7

Upstream product

• 40098-26-8 methyl 7-(3-hydroxy-5-oxocyclopent-1-en-1-yl)heptanoate 
• 32561-42-5 methyl 2-methoxy-4-hydroxy-5-oxocyclopent-1-eneheptanoate 
• 60934-42-1 7-{5-oxo-3-[(tetrahydro-2H-pyran-2-yl)oxy]cyclopent-1-en-1-yl}heptanoic acid methyl ester 
• 65025-95-8 (3aR,4S,5R,6aS)-4-({[dimethyl(2-methyl-2-propanyl)silyl]oxy}methyl)-5-(tetrahydro-2H-pyran-2-yloxy)hexahydro-2H-cyclopenta[b]furan-2-one 
• 31752-99-5 (-)-Corey lactone 5-(4-phenylbenzoate) 
• 58682-77-2 (4-methyloct-1-yn-4-yloxy)triethylsilane 
• 58682-78-3 (+/-)-4-Methyl-4-triethylsilyloxy-trans-1-octenyliodid 
• 197523-79-8 (Z)-7-[(1R,2S,3R,5S)-5-Acetoxy-2-(tert-butyl-dimethyl-silanyloxymethyl)-3-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-hept-5-enoic acid methyl ester 
• 61302-48-5 methyl 7-((1R,2R,3R,5S)-5-acetoxy-2-formyl-3-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)heptanoate 
• 61302-47-4 methyl 7-((1R,2S,3R,5S)-5-acetoxy-2-hydroxymethyl-3-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)heptanoate 
• 62137-77-3 (Z)-7-[(1R,2R,3R,5S)-5-Acetoxy-2-hydroxymethyl-3-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-hept-5-enoic acid methyl ester 
• 65025-96-9 methyl (5Z)-7-[(1R,2S,3R,5S)-2-({[dimethyl(2-methyl-2-propanyl)silyl]oxy}methyl)-5-hydroxy-3-(tetrahydro-2H-pyran-2-yloxy)cyclopentyl]-5-heptenoate 
• 84172-57-6 (Z)-7-[(1R,2S,3R,5S)-2-(t-butyldimethylsilyloxymethyl)-5-hydroxy-3-(2-tetrahydropyranyloxy)cyclopentyl]-5-heptenoic acid 
• 58707-50-9 (3aR,4S,5R,6aS)-4-((tert-butyldimethylsilyloxy)methyl)-5-hydroxyhexahydro-2H-cyclopenta[b]furan-2-one 

Relevant academic research and scientific papers

Prostanoids: Synthesis of enantiomers of 15-deoxy-16-hydroxy-16-methylprostaglandin E1

Four optically pure isomers of methyl 11,16-dihydroxy-16-methyl-9-oxoprost-13-enoate (1a-1d) were synthesized using an approach reverse to the classical Corey procedure, the key intermediates being the easily accessible (-)- and (+)-enantiomers of the Corey lactone, 2a and 2b.

Cyclopenteneheptenoic acid derivatives and method of preparation thereof

This invention relates to a novel cyclopenteneheptenoic acid derivative having the following formula STR1 wherein R1 is hydrogen, --COCH3, --COCF3, --CO--phenyl, or a hydroxyl protecting group such as tetrahydropyranyl, tetrahydrofuranyl, or tri-lower alkylsilyl; wherein R2 is --CH2 OR1, --COOH, --COOR, --CHO, --CH2 --OSi(R12)3, STR2 wherein R is lower alkyl and each R12 is independently lower alkyl or aryl; and wherein Y is ethylene, cis-vinylene, trans-vinylene, or acetylene. Also disclosed is a novel process for preparation of the above-defined cyclopenteneheptenoic acid derivative. This process involves coupling of a higher order cuprate complex with a chiral cyclopentene compound. The resultant product is particularly useful as a starting compound for high yield synthesis of optically active prostaglandins.